Joachim Stangier

Summary

Affiliation: Boehringer Ingelheim

Publications

  1. ncbi Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran
    Joachim Stangier
    Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharma GmbH and Co KG, Biberach an der Riss, Germany
    Blood Coagul Fibrinolysis 23:138-43. 2012
  2. ncbi Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study
    Joachim Stangier
    Boehringer Ingelheim Pharma GmbH and Co KG, Biberach, Germany
    Clin Pharmacokinet 49:259-68. 2010
  3. ncbi Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor
    Joachim Stangier
    Department of Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharma GmbH and Co KG, Birkendorfer Strasse, Biberach an der Riss, Germany
    Clin Appl Thromb Hemost 15:9S-16S. 2009
  4. ncbi Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics
    Joachim Stangier
    Boehringer Ingelheim Pharma GmbH and Co KG, Biberach an der Riss, Germany
    Am J Cardiovasc Drugs 9:59-68. 2009
  5. ncbi Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate
    Joachim Stangier
    Boehringer Ingelheim Pharma GmbH and Co KG, Biberach, Germany
    Clin Pharmacokinet 47:285-95. 2008
  6. ncbi Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects
    Joachim Stangier
    Boehringer Ingelheim Pharma GmbH and Co KG, Biberach, Germany
    Clin Pharmacokinet 47:47-59. 2008
  7. ncbi The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects
    Joachim Stangier
    Boehringer Ingelheim Pharma GmbH and Co KG, Ingelheim, Germany
    Br J Clin Pharmacol 64:292-303. 2007
  8. ncbi Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity
    Joanne van Ryn
    Department of Drug Discovery Support, Boehringer Ingelheim Pharma GmbH and Co KG, Biberach an der Riss, Germany
    Thromb Haemost 103:1116-27. 2010
  9. ncbi Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement
    Joachim Stangier
    Department of Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharma GmbH and Co KG, Birkendorfer Strasse, Biberach an der Riss, D-88397, Germany
    J Clin Pharmacol 45:555-63. 2005
  10. ncbi Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification
    Andreas Clemens
    Boehringer Ingelheim Pharma GmbH and Co KG, Ingelheim, Germany
    Curr Med Res Opin 28:195-201. 2012

Collaborators

Detail Information

Publications16

  1. ncbi Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran
    Joachim Stangier
    Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharma GmbH and Co KG, Biberach an der Riss, Germany
    Blood Coagul Fibrinolysis 23:138-43. 2012
    ..The use of this rapid, established, standardized and calibrated assay should provide accurate and consistent results when assessing the anticoagulant activity of dabigatran...
  2. ncbi Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study
    Joachim Stangier
    Boehringer Ingelheim Pharma GmbH and Co KG, Biberach, Germany
    Clin Pharmacokinet 49:259-68. 2010
    ..A decrease in the dose and/or an increase in the administration interval in these patients may be appropriate. In patients with ESRD, dabigatran can be partly removed from the plasma by haemodialysis...
  3. ncbi Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor
    Joachim Stangier
    Department of Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharma GmbH and Co KG, Birkendorfer Strasse, Biberach an der Riss, Germany
    Clin Appl Thromb Hemost 15:9S-16S. 2009
    ....
  4. ncbi Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics
    Joachim Stangier
    Boehringer Ingelheim Pharma GmbH and Co KG, Biberach an der Riss, Germany
    Am J Cardiovasc Drugs 9:59-68. 2009
    ....
  5. ncbi Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate
    Joachim Stangier
    Boehringer Ingelheim Pharma GmbH and Co KG, Biberach, Germany
    Clin Pharmacokinet 47:285-95. 2008
    ....
  6. ncbi Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects
    Joachim Stangier
    Boehringer Ingelheim Pharma GmbH and Co KG, Biberach, Germany
    Clin Pharmacokinet 47:47-59. 2008
    ....
  7. ncbi The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects
    Joachim Stangier
    Boehringer Ingelheim Pharma GmbH and Co KG, Ingelheim, Germany
    Br J Clin Pharmacol 64:292-303. 2007
    ..Two double-blind, randomized trials were undertaken to investigate the pharmacokinetics (PK), pharmacodynamics (PD) and tolerability of orally administered dabigatran etexilate in healthy male subjects...
  8. ncbi Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity
    Joanne van Ryn
    Department of Drug Discovery Support, Boehringer Ingelheim Pharma GmbH and Co KG, Biberach an der Riss, Germany
    Thromb Haemost 103:1116-27. 2010
    ....
  9. ncbi Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement
    Joachim Stangier
    Department of Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharma GmbH and Co KG, Birkendorfer Strasse, Biberach an der Riss, D-88397, Germany
    J Clin Pharmacol 45:555-63. 2005
    ..These pharmacokinetic characteristics confirm the suitability of this oral solid dosage form for use in future clinical trials...
  10. ncbi Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification
    Andreas Clemens
    Boehringer Ingelheim Pharma GmbH and Co KG, Ingelheim, Germany
    Curr Med Res Opin 28:195-201. 2012
    ..Based on its pharmacokinetic profile, dabigatran is dosed twice daily. This analysis provides a quantitative rationale for the selection of the dose regimen in this population...
  11. ncbi Pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects after oral administration of dabigatran etexilate
    Sebastian Hartter
    Translational Medicine, Boehringer Ingelheim Pharma GmbH and Co KG, Biberach, Germany
    Thromb Haemost 107:260-9. 2012
    ....
  12. ncbi The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans
    Stefan Blech
    Boehringer Ingelheim Pharma GmbH and Co KG, Department of Drug Metabolism and Pharmacokinetics, Biberach, Germany
    Drug Metab Dispos 36:386-99. 2008
    ..o. administration of dabigatran etexilate and that the potential for clinically relevant interactions between dabigatran and drugs metabolized by cytochrome P450 is low...
  13. ncbi Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement surgery
    Inaki F Troconiz
    Boehringer Ingelheim Pharma GmbH and Co KG, Birkendorfer Strasse 68, 88397 Biberach, Germany
    J Clin Pharmacol 47:371-82. 2007
    ..As a consequence, the rate of absorption is reduced and interindividual variability in drug exposure increased. On the following days, the disposition in plasma of BIBR 953 ZW is less variable...
  14. ncbi Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study)
    Michael D Ezekowitz
    Lankenau Institute for Medical Research and The Heart Center, Wynnewood, PA, USA
    Am J Cardiol 100:1419-26. 2007
    ..The 2 highest doses of dabigatran suppress D-dimer concentrations. Serious liver toxicity was not seen. The significance of the increase of DTB2 concentrations in dabigatran-treated patients needs resolution...
  15. ncbi Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis
    Karl-Heinz Liesenfeld
    Boehringer Ingelheim Pharma GmbH and Co, KG, Ingelheim, Germany
    Br J Clin Pharmacol 62:527-37. 2006
    ..Blood coagulation prolongation was most pronounced following surgery. Data suggest that ECT provides a more precise description of the anticoagulant effect than aPTT...
  16. ncbi In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist
    Marc P Maillard
    Division of Hypertension and Vascular Medicine, University Hospital of Lausanne, CHUV CH 1011 Lausanne, Switzerland
    J Pharmacol Exp Ther 302:1089-95. 2002
    ..Taken together, our in vitro data show that the insurmountable antagonism of telmisartan is due at least in part to its very slow dissociation from AT1 receptors...